Viking Therapeutics is trading 5.07% down now at $38.78 as investors appeared to take profits after the September 22 surge.
- VK2735 maintenance-study data showed patients retained up to 97% of prior weight loss with every-other-week dosing and up to 90% with monthly dosing.
- Shares gained 35.67% to $40.85 on September 22; no stronger new company-specific negative catalyst was identified.